MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
NCT ID: NCT06534437
Last Updated: 2025-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
178 participants
INTERVENTIONAL
2024-12-05
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma
* Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma Group 1 patients will be treated for a maximum of 12 cycles. One cycle is 21 days. Group 2 with be treated until the disease progresses, therefore treatment duration is dependent on the number of treatment cycles a participant receives prior to progression.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
NCT03484702
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
NCT03141203
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
NCT03403725
Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients
NCT02374424
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
NCT04774068
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Part 1 (safety run-in) and Part 2 (enrichment): patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will receive either 150 mg or 125 mg of MEN1703 along with glofitamab. Patients who have exhausted all standard treatment options (group 2) will receive 125 mg of MEN1703 as a single-agent.
Part 3 (optional randomized comparison): Patients who are naïve to treatment with an anti-CD3xCD20 bispecific antibody therapy will be randomized to receive either MEN1703 (Dapolsertib hydrochloride) at a dose selected from part 2 in combination with glofitamab or glofitamab alone.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MEN1703 + glofitamab
• Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will be given MEN1703 orally at a dose of 150 mg daily for 7 days or 125 mg daily for 14 days, in 21-day cycles for a maximum of 12 cycles, in combination with glofitamab administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (parts 1, 2, 3)).
All participants will be administered 1,000 mg of obinutuzumab as an IV infusion on cycle 1 day 1.
• Participants who have exhausted all standard treatment options (group 2) will receive MEN1703 as a single-agent, at a dose of 125 mg orally every-day for 14 consecutive days in consecutive 21-day treatment cycles, until progressive disease (parts 1 and 2).
MEN1703
MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
Glofitamab
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
Gofitamab
Participants who are naïve to treatment with an anti-CD3xCD20 bispecific antibody (group 1) will receive glofitamab as a single-agent administered as an IV infusion in a step-up dosing schedule starting with 2.5 mg on day 8 of cycle 1, and10 mg on day 15 of cycle 1, and 30 mg on day 1 from cycle 2 onward until disease progression or withdrawal, for a maximum of 12 cycles (part 3).
Glofitamab
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MEN1703
MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3).
Glofitamab
Glofitamab is a bispecific monoclonal antibody that binds bivalently to CD20 expressed on the surface of B-cells and monovalently to CD3 in the T-cell receptor complex expressed on the surface of T-cells.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Documented histological confirmation of aggressive B-cell non-Hodgkin lymphoma including DLBCL NOS and transformed indolent B-cell lymphoma
3. Relapsed or refractory disease having received at least 2 prior lines of systemic treatment and, naïve to anti-CD3xCD20 bispecific antibody treatment (group 1) or exhausted all standard, available treatment options (group 2)
4. At least 1 measurable site of disease based on computed tomography (CT) or positron emission tomography (PET)-CT scan with involvement of 2 or more clearly demarcated lesions and or nodes.
5. Availability of lymph node tissue at Screening (or archival sample) (part 2 participants only)
6. Life expectancy of ≥12 weeks.
7. Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
8. Adequate organ function at Screening
9. Adequate hematologic function
Exclusion Criteria
2. Received anti-cancer treatments, including cytotoxic chemotherapy, radiotherapy, hormonal therapy, biologic, immunotherapy, or investigational drugs within 14 days or 5 half-lives (whichever is shorter) before the first dose of study drug. Prior treatment with CAR-T cell or an anti-CD3xCD20 bispecific antibody therapy (permitted for Group 2 only), requires a wash out period of ≥4 weeks.
3. Concurrent participation in another therapeutic clinical study.
4. Ongoing clinically significant toxicity (for example, alopecia is not clinically significant) from any prior anti-cancer therapy that has not resolved to Grade 1 or less prior to the first dose of study drug.
5. Prior treatment with a PIM inhibitor.
6. Group 1 only: Any prior therapy with a bispecific antibody targeting CD3 and CD20.
7. Known risk of allergy to the study drugs, MEN1703 (group 1 and 2) or glofitamab (group 1) or their excipients
8. Contraindication to all uric acid lowering agents.
9. Major surgery within 1 month prior to first dose of study drug.
10. Hematopoietic stem cell transplant within 4 months prior to first dose of study drug.
11. Requires systemic immune-modulating therapy (regardless of dose) or has confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression.
12. Exposed to live or live attenuated vaccine(s) within 4 weeks prior to signing the informed consent form (ICF).
13. Evidence of ongoing and uncontrolled systemic bacterial, fungal, or viral infection, except for documented Grade Common Terminology Criteria for Adverse Events (CTCAE) ≤2 infections with evidence of improvement or without evidence of worsening infection.
14. Known human immunodeficiency virus (HIV) infection
15. Current active liver disease from any cause
16. Ongoing drug-induced pneumonitis.
17. Ongoing inflammatory bowel disease.
18. Active known second malignancy
19. Received an agent known to be a sensitive CYP2D6 substrate or a CYP2D6 substrate with a narrow therapeutic range, a strong or moderate CYP2D6 inhibitor, or a BCRP inhibitor within 14 days or 5 half-lives (whichever is shorter), prior to the first dose of study drug.
20. Cardiac dysfunction is defined as myocardial infarction within 6 months of study entry, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, or poorly controlled angina.
21. Receiving treatment for active, ongoing thromboembolic event. Note: Does not apply to prophylactic treatment to prevent or avoid reoccurrence of a prior resolved event. To review with Medical Monitor where further risk assessment is needed.
22. History of serious ventricular arrhythmia (e.g., VT or VF, ≥3 beats in a row), or QT interval corrected for heart rate (QTc) ≥480 ms.
Note: QTc values up to 500 ms will be acceptable where patient's medical history e.g., bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled.
23. Any disease, syndrome or condition which may significantly affect drug intake via oral route.
24. Planning to become pregnant or breastfeed during treatment and for 1 month after the last dose of study drug.
25. Any other prior or current medical condition, intercurrent illness, surgical history, physical or 12-lead electrocardiogram (ECG) findings, laboratory abnormalities, or extenuating circumstance (e.g., alcohol or drug addiction) that, in the investigator's opinion, could jeopardize patient safety or interfere with the objectives of the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Menarini Group
INDUSTRY
Ryvu Therapeutics SA
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Le Mans
Le Mans, , France
CHU de Lille - Hôpital Claude Huriez
Lille, , France
CHU de Limoges - CHU Dupuytren
Limoges, , France
Hospices Civils De Lyon - Hôpital Lyon Sud
Lyon, , France
CHU Montpellier - Hôpital Saint Eloi
Montpellier, , France
APHP - Hôpital Pitié-Salpêtrière
Paris, , France
CHU de Bordeaux - Hôpital Haut-Lévêque
Pessac, , France
Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
Biała Podlaska, , Poland
IN-VIVO Bydgoszcz Sp. z o.o.
Bydgoszcz, , Poland
Klinika Hematologii I Transplantologii Uck
Gdansk, , Poland
Szpitale Pomorskie Sp. z o.o.
Gdynia, , Poland
Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy
Gliwice, , Poland
Pratia Hematologia Sp. z o.o.
Katowice, , Poland
Pratia MCM Kraków
Krakow, , Poland
SP ZOZ Szpital Uniwersytecki w Krakowie
Krakow, , Poland
Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie
Olsztyn, , Poland
Aidport Sp. z o.o.
Skórzewo, , Poland
Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu
Torun, , Poland
Lux Med Onkologia Sp. z o.o.
Warsaw, , Poland
Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy
Warsaw, , Poland
Hospital Universitari Vall D Hebron
Barcelona, , Spain
Clinica Universidad De Navarra
Madrid, , Spain
MD Anderson Cancer Center
Madrid, , Spain
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, , Spain
Hospital Clínico Uni versitario Virgen de la Arrixaca
Murcia, , Spain
Clinica Universidad De Navarra
Pamplona, , Spain
Hospital Universitario De Navarra
Pamplona, , Spain
Hospital Universitario De Salamanca
Salamanca, , Spain
Hospital Universitario Virgen De La Macarena
Seville, , Spain
Hospital Universitario Miguel Servet
Zaragoza, , Spain
Beatson West of Scotland Cancer Centre
Glasgow, , United Kingdom
The Royal Marsden Hospital
London, , United Kingdom
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Plymouth Hospitals NHS Trust
Plymouth, , United Kingdom
The Royal Marsden Hospital
Sutton, , United Kingdom
St George's Hospital
Tooting, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Piotr Centkowski, MD PhD
Role: primary
Małgorzata Krawczyk-Kuliś, Prof.
Role: primary
Sebastian Grosicki, Prof.
Role: primary
Wojciech Jurczak, Prof.
Role: primary
Janusz Hałka, MD PhD
Role: primary
Dominik Chraniuk, MD
Role: primary
Joanna Barankiewicz, MD PhD
Role: primary
Krzysztof Gawroński, MD PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JASPIS-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.